Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | glutaminase | Starlite/ChEMBL | No references |
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | dihydroorotate dehydrogenase 2 | 0.0532 | 1 | 1 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.0208 | 0.348 | 1 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.0208 | 0.348 | 1 |
Trypanosoma cruzi | dihydroorotate dehydrogenase (fumarate), putative | 0.0532 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0129 | 0.0174 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.0129 | 0.0103 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0512 | 0.0821 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.4351 | 0.7321 |
Plasmodium falciparum | dihydroorotate dehydrogenase | 0.0532 | 1 | 0.5 |
Plasmodium vivax | dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.0532 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.0512 | 0.0821 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.0532 | 1 | 1 |
Loa Loa (eye worm) | glutaminase | 0.033 | 0.5934 | 1 |
Leishmania major | dihydroorotate dehydrogenase | 0.0532 | 1 | 0.5 |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 0.5049 | 0.6394 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0512 | 0.0486 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.0208 | 0.348 | 1 |
Loa Loa (eye worm) | glutaminase 2 | 0.033 | 0.5934 | 1 |
Onchocerca volvulus | 0.0286 | 0.5049 | 1 | |
Echinococcus granulosus | histone lysine methyltransferase setb | 0.0036 | 0.0027 | 0.0077 |
Schistosoma mansoni | glutaminase | 0.033 | 0.5934 | 0.5923 |
Brugia malayi | Dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.0532 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydroorotate dehydrogenase 2 | 0.0532 | 1 | 0.5 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.0208 | 0.348 | 1 |
Schistosoma mansoni | dihydroorotate dehydrogenase | 0.0532 | 1 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0512 | 0.0486 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.4351 | 0.4336 |
Mycobacterium leprae | Probable dihydroorotate dehydrogenase PyrD | 0.0532 | 1 | 0.5 |
Entamoeba histolytica | dihydropyrimidine dehydrogenase, putative | 0.0208 | 0.348 | 0.5 |
Brugia malayi | Zinc finger, C2H2 type family protein | 0.0208 | 0.348 | 0.3462 |
Brugia malayi | glutaminase DH11.1 | 0.033 | 0.5934 | 0.5923 |
Mycobacterium tuberculosis | Probable dihydroorotate dehydrogenase PyrD | 0.0532 | 1 | 0.5 |
Trypanosoma brucei | dihydroorotate dehydrogenase (fumarate) | 0.0532 | 1 | 0.5 |
Toxoplasma gondii | dihydroorotate dehydrogenase reveal, putative | 0.0532 | 1 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.0129 | 0.0103 |
Trichomonas vaginalis | glutaminase, putative | 0.033 | 0.5934 | 1 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.0532 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.631 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 4.6535 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.